medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-3-92-97medsovet-66Research ArticleПрактикаPracticeВилдаглиптин: известное и неизвестноеVildagliptin: the known and unknownМоргуновЛ. Ю.MorgunovL. Y.noemail@neicon.ruМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation201630122016039297Copyright © Моргунов Л.Ю., 20162016Моргунов Л.Ю.Morgunov L.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/66

Вилдаглиптин - инновационный эффективный ингибитор ДПП-4, используемый в качестве моно-или комбинированной терапии сахарного диабета 2-го типа. Препарат устойчиво снижает уровень гликированного гемоглобина, не увеличивает риск гипогликемии и сердечно-сосудистой патологии. Результаты многочисленных клинических исследований подтвердили эффективность и безопасность вилдаглиптина, а также продемонстрировали новые широкие возможности в его применении.

Vildagliptin is an innovative, effective DPP-4 inhibitor to be used as mono- or combination therapy of type 2 diabetes. The drug consistently reduces the level of glycated hemoglobin and does not increase the risk of hypoglycemia and cardiovascular disease. Numerous clinical studies have demonstrated the efficacy and safety of vildagliptin and opened new prospects for its application.

вилдаглиптинингибиторы ДПП-4сахарный диабет 2-го типабезопасностьvildagliptinDPP-4 inhibitorstype 2 diabetessafetyReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. Вып. 7. М., 2015.Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. Вып. 7. М., 2015.Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М., 2010. C. 92.Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М., 2010. C. 92.Аметов А.С. Сахарный диабет 2 типа: проблемы и решения. Москва, ГЭОТАР-Медиа, 2011, 704 с.Аметов А.С. Сахарный диабет 2 типа: проблемы и решения. Москва, ГЭОТАР-Медиа, 2011, 704 с.Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol, 2015 Jul 15. doi: 10.1111/1440-1681.12455.Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol, 2015 Jul 15. doi: 10.1111/1440-1681.12455.Garber A et al."Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea". Diabetes, Obesity and Metabolism, 2008, 10: 1326-463.Garber A et al."Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea". Diabetes, Obesity and Metabolism, 2008, 10: 1326-463.Анциферов МБ. Клинические аспекты применения иДПП-4 в комбинации с метформином: преимущества для разных групп пациентов. Фарматека, 2011, 3(216): 50-55.Анциферов МБ. Клинические аспекты применения иДПП-4 в комбинации с метформином: преимущества для разных групп пациентов. Фарматека, 2011, 3(216): 50-55.Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol, 2015 Sep 29, 14: 129. doi: 10.1186/s12933-015-0294-0.Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol, 2015 Sep 29, 14: 129. doi: 10.1186/s12933-015-0294-0.Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG. Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord, 2015 Aug 22, 14: 68. doi: 10.1186/ s40200-015-0194-6.Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG. Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord, 2015 Aug 22, 14: 68. doi: 10.1186/ s40200-015-0194-6.Deacon CF, Lebovitz HE. A Comparative Review of DPP-4 Inhibitors and Sulphonylureas. Diabetes Obes Metab, 2015 Nov 24. doi: 10.1111/dom.12610.Deacon CF, Lebovitz HE. A Comparative Review of DPP-4 Inhibitors and Sulphonylureas. Diabetes Obes Metab, 2015 Nov 24. doi: 10.1111/dom.12610.Bosi E, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes Care, 2007, 30: 890-95.Bosi E, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes Care, 2007, 30: 890-95.Hirose T, Suzuki M, Tsumiyama I. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Ther, 2015 Dec, 6(4): 559-571.Hirose T, Suzuki M, Tsumiyama I. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Ther, 2015 Dec, 6(4): 559-571.Barnett AH, Charbonnel B, Moses RG, Kalra S. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin, 2015, 31(10): 1919-31. doi: 10.1185/03007995.2015.1081589.Barnett AH, Charbonnel B, Moses RG, Kalra S. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin, 2015, 31(10): 1919-31. doi: 10.1185/03007995.2015.1081589.Моргунов Л.Ю. Возможности применения вилдаглиптина в комбинации с инсулинотерапией у пациентов с острым инфарктом миокарда. Материалы IV Международного Форума кардиологов и терапевтов. Москва, 2014, стр. 145.Моргунов Л.Ю. Возможности применения вилдаглиптина в комбинации с инсулинотерапией у пациентов с острым инфарктом миокарда. Материалы IV Международного Форума кардиологов и терапевтов. Москва, 2014, стр. 145.Mclnnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao O, Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab, 2015 Nov, 17(11): 1085-92. doi: 10.1111/dom.12548.Mclnnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao O, Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab, 2015 Nov, 17(11): 1085-92. doi: 10.1111/dom.12548.Khan S, Khan S, Panda BP, Akhtar M, Najmi AK. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. Expert Opin Ther Targets, 2015 Dec, 19(12): 1607-16. doi: 10.1517/14728222.2016.1086338.Khan S, Khan S, Panda BP, Akhtar M, Najmi AK. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. Expert Opin Ther Targets, 2015 Dec, 19(12): 1607-16. doi: 10.1517/14728222.2016.1086338.Cosenso-Martin LN, Giollo-Junior LT, Martineli DD, Cesarino CB, Nakazone MA, Cipullo JP Vilela-Martin JF. Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr, 2015 Aug 26, 7: 70. doi: 10.1186/s13098-015-0062-z.Cosenso-Martin LN, Giollo-Junior LT, Martineli DD, Cesarino CB, Nakazone MA, Cipullo JP Vilela-Martin JF. Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr, 2015 Aug 26, 7: 70. doi: 10.1186/s13098-015-0062-z.Hissa MR, Cavalcante LL, Guimaraes SB, Hissa MN. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetol Metab Syndr, 2015 Jul 11, 7: 62. doi: 10.1186/s13098-015-0058-8.Hissa MR, Cavalcante LL, Guimaraes SB, Hissa MN. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetol Metab Syndr, 2015 Jul 11, 7: 62. doi: 10.1186/s13098-015-0058-8.Cosenso-Martin LN, Giollo-Junior LT, Vilela-Martin JF. DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report. Medicine (Baltimore), 2015 Jul, 94(27): e1068. doi: 10.1097/ MD.0000000000001068.Cosenso-Martin LN, Giollo-Junior LT, Vilela-Martin JF. DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report. Medicine (Baltimore), 2015 Jul, 94(27): e1068. doi: 10.1097/ MD.0000000000001068.Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A, Foley JE, Taylor R. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab, 2015 Apr, 100(4): 1578-85. doi: 10.1210/jc.2014-3794.Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A, Foley JE, Taylor R. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab, 2015 Apr, 100(4): 1578-85. doi: 10.1210/jc.2014-3794.El-Sherbeeny NA, Nader MA. The protective effect of vildagliptin in chronic experimental cyclo-sporine A-induced hepatotoxicity. Can J Physiol Pharmacol, 2015 Aug 24: 1-6. [Epub ahead of print]El-Sherbeeny NA, Nader MA. The protective effect of vildagliptin in chronic experimental cyclo-sporine A-induced hepatotoxicity. Can J Physiol Pharmacol, 2015 Aug 24: 1-6. [Epub ahead of print]Mera J, Okada E, Okuda M, Ota T, Sibata S, Uchida S. Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis. J Diabetes Metab Disord, 2015 Nov 5, 14: 83. doi: 10.1186/s40200-015-0214-6.Mera J, Okada E, Okuda M, Ota T, Sibata S, Uchida S. Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis. J Diabetes Metab Disord, 2015 Nov 5, 14: 83. doi: 10.1186/s40200-015-0214-6.Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2015 Dec 29. Epub ahead of print.Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2015 Dec 29. Epub ahead of print.Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev, 2015 Sep 29. doi: 10.1002/dmrr.2723.Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev, 2015 Sep 29. doi: 10.1002/dmrr.2723.Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes Metab Syndr Obes, 2015 Apr 16, 8: 207-11. doi: 10.2147/DMSO.S54683.Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes Metab Syndr Obes, 2015 Apr 16, 8: 207-11. doi: 10.2147/DMSO.S54683.Algorithms of specialized medical care to patients with diabetes. Ed. by I.I. Dedov, M.V. Shestakova. Vol. 7. Moscow, 2015.Algorithms of specialized medical care to patients with diabetes. Ed. by I.I. Dedov, M.V. Shestakova. Vol. 7. Moscow, 2015.Dedov I.I., Shestakova M.V. Iincretins: a new milestone in the treatment of type 2 diabetes. М., 2010. P. 92.Dedov I.I., Shestakova M.V. Iincretins: a new milestone in the treatment of type 2 diabetes. М., 2010. P. 92.Ametov A.S. Diabetes mellitus type 2: issues and solutions. Moscow, GEOTAR Media, 2011, 704 p.Ametov A.S. Diabetes mellitus type 2: issues and solutions. Moscow, GEOTAR Media, 2011, 704 p.Antsiferov M.B. Clinical aspects of the use of DPP-4 inhibitors in combination with metformin: benefits for different groups of patients. Pharmateka,2011, 3(216): 50-55Antsiferov M.B. Clinical aspects of the use of DPP-4 inhibitors in combination with metformin: benefits for different groups of patients. Pharmateka,2011, 3(216): 50-55Morgunov L.Y. Possible applications of vildagliptin in combination with insulin therapy in patients with acute myocardial infarction. Proceedings of the IV International Forum of cardiologists and physicians. Moscow, 2014, pp. 145.Morgunov L.Y. Possible applications of vildagliptin in combination with insulin therapy in patients with acute myocardial infarction. Proceedings of the IV International Forum of cardiologists and physicians. Moscow, 2014, pp. 145.

The authors declare that there are no conflicts of interest present.